Skip to main content
Fig. 6 | Experimental Hematology & Oncology

Fig. 6

From: The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

Fig. 6

KW-2478 synergistically functioned with imatinib to induce apoptosis and growth inhibition in CML cells. a A CCK-8 assay was used to determine the combined effects of KW-2478 and imatinib on cell viability of K562 and K562/G01 cells. b The combination index of K562 or K562/G01 cells was analysed using CompuSyn software. c Following treatment with KW-2478, imatinib or both, cell apoptosis was detected by flow cytometry. d Statistical analysis of the apoptosis rates of K562 and K562/G01 cells treated with KW-2478, imatinib or both

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us